结直肠癌DNA甲基化标志物

• Format: Patent
• Language: Chinese
• Published: 23.12.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATIONTECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING ORPROCESSING OF MEDICAL OR HEALTHCARE DATA; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

本发明提供一种用于预测结直肠癌(CRC)风险的DNA甲基化标志物集，所述标志物集包括ESR1、ZNF132、ZNF229、ZNF542和ZNF677；本发明还提供一种用于测定DNA甲基化标志物集的试剂盒；本发明还提供一种DNA甲基化标志物集用于制备预测受试者中结直肠癌(CRC)风险的试剂盒的用途。本发明还提供一种获取DNA甲基化标志物集的方法，本发明还提供一种用于评估结直肠癌DNA甲基化标志物集诊断准确性的方法，本发明提出了预测结直肠癌(CRC)风险的DNA甲基化标志物集并构建了诊断模型(模型1、模型2和模型3)，可用于CRC筛查与早期诊断，并优于目前广泛使用的SEPT9方法；可推广应用于结直肠癌的诊断。 The invention provides a DNA methylation marker set for predicting a colorectal cancer (CRC) risk. The marker set comprises ESR1, ZNF132, ZNF229, ZNF542 and ZNF677. The invention further provides a kit for determination of the DNA methylation marker set, and the invention further provides usage of the DNA methylation marker set in preparation of the kit for predicting the colorectal cancer (CRC) risk of a subject. The invention further provides a method for obtaining the DNA methylation marker set, the invention further provides a method for evaluating the diagnostic accuracy of DNA methylation marker set in colorectal cancer, the DNA methylation marker set for predicting a colorectal cancer (CRC) risk is pr